336 related articles for article (PubMed ID: 28394340)
1. Selective targeting p53
Lu W; Cheng F; Yan W; Li X; Yao X; Song W; Liu M; Shen X; Jiang H; Chen J; Li J; Huang J
Oncogene; 2017 Aug; 36(33):4719-4731. PubMed ID: 28394340
[TBL] [Abstract][Full Text] [Related]
2. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
[TBL] [Abstract][Full Text] [Related]
3. A G3BP1-Interacting lncRNA Promotes Ferroptosis and Apoptosis in Cancer via Nuclear Sequestration of p53.
Mao C; Wang X; Liu Y; Wang M; Yan B; Jiang Y; Shi Y; Shen Y; Liu X; Lai W; Yang R; Xiao D; Cheng Y; Liu S; Zhou H; Cao Y; Yu W; Muegge K; Yu H; Tao Y
Cancer Res; 2018 Jul; 78(13):3484-3496. PubMed ID: 29588351
[TBL] [Abstract][Full Text] [Related]
4. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
[TBL] [Abstract][Full Text] [Related]
5. ZCCHC10 suppresses lung cancer progression and cisplatin resistance by attenuating MDM2-mediated p53 ubiquitination and degradation.
Ning Y; Hui N; Qing B; Zhuo Y; Sun W; Du Y; Liu S; Liu K; Zhou J
Cell Death Dis; 2019 May; 10(6):414. PubMed ID: 31138778
[TBL] [Abstract][Full Text] [Related]
6. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of MDM2 inhibitor MI-219 against lung cancer cells alone or in combination with MDM2 knockdown, a XIAP inhibitor or etoposide.
Zheng M; Yang J; Xu X; Sebolt JT; Wang S; Sun Y
Anticancer Res; 2010 Sep; 30(9):3321-31. PubMed ID: 20944104
[TBL] [Abstract][Full Text] [Related]
8. XI-011 enhances cisplatin-induced apoptosis by functional restoration of p53 in head and neck cancer.
Roh JL; Park JY; Kim EH
Apoptosis; 2014 Nov; 19(11):1594-602. PubMed ID: 25113507
[TBL] [Abstract][Full Text] [Related]
9. TNFAIP8 promotes the proliferation and cisplatin chemoresistance of non-small cell lung cancer through MDM2/p53 pathway.
Xing Y; Liu Y; Liu T; Meng Q; Lu H; Liu W; Hu J; Li C; Cao M; Yan S; Huang J; Wang T; Cai L
Cell Commun Signal; 2018 Jul; 16(1):43. PubMed ID: 30064446
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the p53-MDM2 interaction by adenovirus delivery of ribosomal protein L23 stabilizes p53 and induces cell cycle arrest and apoptosis in gastric cancer.
Zhang Y; Shi Y; Li X; Du W; Luo G; Gou Y; Wang X; Guo X; Liu J; Ding J; Wu K; Fan D
J Gene Med; 2010 Feb; 12(2):147-56. PubMed ID: 20020415
[TBL] [Abstract][Full Text] [Related]
11. CT‑1042, a novel anticancer agent, exhibits effects by activating p53 and inhibiting survivin.
Yang J; Li L; Xu C; Yang D; Wang S; Yuan S
Oncol Rep; 2018 Jun; 39(6):2759-2768. PubMed ID: 29620221
[TBL] [Abstract][Full Text] [Related]
12. MDM2 small-molecule antagonist RG7112 activates p53 signaling and regresses human tumors in preclinical cancer models.
Tovar C; Graves B; Packman K; Filipovic Z; Higgins B; Xia M; Tardell C; Garrido R; Lee E; Kolinsky K; To KH; Linn M; Podlaski F; Wovkulich P; Vu B; Vassilev LT
Cancer Res; 2013 Apr; 73(8):2587-97. PubMed ID: 23400593
[TBL] [Abstract][Full Text] [Related]
13. Synergistic tumor suppression by coexpression of FHIT and p53 coincides with FHIT-mediated MDM2 inactivation and p53 stabilization in human non-small cell lung cancer cells.
Nishizaki M; Sasaki J; Fang B; Atkinson EN; Minna JD; Roth JA; Ji L
Cancer Res; 2004 Aug; 64(16):5745-52. PubMed ID: 15313915
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
[TBL] [Abstract][Full Text] [Related]
15. Identification of a new class of MDM2 inhibitor that inhibits growth of orthotopic pancreatic tumors in mice.
Wang W; Qin JJ; Voruganti S; Wang MH; Sharma H; Patil S; Zhou J; Wang H; Mukhopadhyay D; Buolamwini JK; Zhang R
Gastroenterology; 2014 Oct; 147(4):893-902.e2. PubMed ID: 25016295
[TBL] [Abstract][Full Text] [Related]
16. Spiro-oxindole derivative 5-chloro-4',5'-diphenyl-3'-(4-(2-(piperidin-1-yl) ethoxy) benzoyl) spiro[indoline-3,2'-pyrrolidin]-2-one triggers apoptosis in breast cancer cells via restoration of p53 function.
Saxena R; Gupta G; Manohar M; Debnath U; Popli P; Prabhakar YS; Konwar R; Kumar S; Kumar A; Dwivedi A
Int J Biochem Cell Biol; 2016 Jan; 70():105-17. PubMed ID: 26556313
[TBL] [Abstract][Full Text] [Related]
17. A Combination RNAi-Chemotherapy Layer-by-Layer Nanoparticle for Systemic Targeting of KRAS/P53 with Cisplatin to Treat Non-Small Cell Lung Cancer.
Gu L; Deng ZJ; Roy S; Hammond PT
Clin Cancer Res; 2017 Dec; 23(23):7312-7323. PubMed ID: 28912139
[No Abstract] [Full Text] [Related]
18. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.
Deben C; Wouters A; Op de Beeck K; van Den Bossche J; Jacobs J; Zwaenepoel K; Peeters M; Van Meerbeeck J; Lardon F; Rolfo C; Deschoolmeester V; Pauwels P
Oncotarget; 2015 Sep; 6(26):22666-79. PubMed ID: 26125230
[TBL] [Abstract][Full Text] [Related]
19. The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer.
Roh JL; Ko JH; Moon SJ; Ryu CH; Choi JY; Koch WM
Cancer Lett; 2012 Dec; 325(1):35-41. PubMed ID: 22634494
[TBL] [Abstract][Full Text] [Related]
20. A genome-wide siRNA screen for regulators of tumor suppressor p53 activity in human non-small cell lung cancer cells identifies components of the RNA splicing machinery as targets for anticancer treatment.
Siebring-van Olst E; Blijlevens M; de Menezes RX; van der Meulen-Muileman IH; Smit EF; van Beusechem VW
Mol Oncol; 2017 May; 11(5):534-551. PubMed ID: 28296343
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
